Insulet Stock Plummets 30.61% with $196M Trading Volume Ranking 493rd Amid Omnipod 5 Recall

On June 25, 2025, Insulet Corporation (PODD) experienced a significant decline in its stock price, with a trading volume of $196 million, marking a 30.61% decrease from the previous day. This placed Insulet at the 493rd position in terms of trading volume for the day.

Insulet's Omnipod 5, an automated insulin delivery system, received FDA clearance in January 2022 for individuals aged six and above with type 1 diabetes. This clearance made Omnipod 5 the first automated insulin delivery system to be approved for this age group, positioning it as a leading solution in the diabetes management market.

On June 5, 2025, the FDA officially classified the recall of Omnipod 5 as a Class II recall. This classification indicates that the product may cause temporary or medically reversible adverse health consequences. The recall was initiated due to potential issues with the device's performance, which could impact its effectiveness in delivering insulin to patients.